Novartis Tests New Drug for Psoriatic Arthritis

The Phase 2 study evaluates a new treatment for adults living with moderate to severe psoriatic arthritis.

Updated on Oct. 28, 2026 in Arthritis

A precision micropipette dispenses a clear droplet into a sterile glass vial in a clean, brightly lit clinical laboratory.
Novartis has initiated a Phase 2 trial for MRT-6160, an investigational molecular glue degrader targeting VAV1 proteins to treat moderate to severe psoriatic arthritis. AI Illustration. Upload story photo >

Live Poll

Do you trust that large-scale corporate pharmaceutical partnerships prioritize patient health over financial gain?

Novartis has launched a Phase 2 clinical trial to evaluate the safety and efficacy of the investigational drug MRT-6160 in adults with moderate to severe psoriatic arthritis. This trial, currently tracking under study identifier NCT07801495, marks the latest step in testing the VAV1-directed molecular glue degrader in immune-mediated conditions.

Why it matters

Psoriatic arthritis is a chronic inflammatory condition that affects a significant portion of those with psoriasis, requiring effective new treatment options to manage joint symptoms. This study seeks to establish if MRT-6160 can safely reduce disease activity in patients who have not responded to existing therapies.

This Phase 2a/b randomized, double-blind, placebo-controlled, multicenter clinical trial (NCT07801495) is evaluating the efficacy and safety of MRT-6160 in patients with moderate to severe psoriatic arthritis. The findings are preliminary, as the study is currently in its early clinical phase.

The players

Novartis

A global pharmaceutical corporation that develops and manufactures treatments for immunology, oncology, and cardiovascular diseases.

Monte Rosa Therapeutics

A biotechnology company focused on developing small-molecule protein degraders to treat immune-mediated diseases and cancer.

The details

MRT-6160 is a VAV1-directed molecular glue degrader, a class of therapy that works by binding to a protein of interest and marking it for destruction by the body's own protein-degradation machinery. By targeting the VAV1 protein, which plays a key role in the signaling pathways of immune cells, the drug aims to dampen the inflammation that drives joint damage in psoriatic arthritis. Novartis is responsible for conducting and funding the trial to determine whether this mechanism provides a clinically meaningful improvement for participants.

Timeline

  1. August 2026: Phase 2 trial for Sjögren's disease was initiated.

  2. October 28, 2026: Novartis announced the start of the psoriatic arthritis study.

Health Landscape

The study of MRT-6160 represents the latest effort to expand the use of protein degradation technology across a wider range of immune-mediated diseases. This approach sits alongside competing biologics and small molecules currently being tested to address inflammatory conditions.

If you are managing moderate to severe psoriatic arthritis, it is worth discussing with your rheumatologist whether your current treatment plan is meeting your goals or if you might be a candidate for clinical research. Always ensure you are reviewing the latest safety data for new treatments via your physician before considering changes to your care.

The takeaway

This trial marks a new phase in testing targeted protein degraders as a potential approach to managing inflammatory arthritis. Patients interested in emerging therapies should prioritize maintaining regular checkups with their rheumatologist to monitor disease activity and current treatment efficacy.

Further reading

For more on how new research is changing the way we approach long-term joint health, explore our Arthritis section.

More information

You can track the progress of this trial and others via the clinical trial study information portal.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you trust that large-scale corporate pharmaceutical partnerships prioritize patient health over financial gain?